MA51988A - Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale - Google Patents

Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale

Info

Publication number
MA51988A
MA51988A MA051988A MA51988A MA51988A MA 51988 A MA51988 A MA 51988A MA 051988 A MA051988 A MA 051988A MA 51988 A MA51988 A MA 51988A MA 51988 A MA51988 A MA 51988A
Authority
MA
Morocco
Prior art keywords
preparation
compounds useful
treating spinal
spinal amyotrophy
amyotrophy
Prior art date
Application number
MA051988A
Other languages
English (en)
Inventor
Luke Green
Nikolai A Naryshkin
Hasane Ratni
Marla L Weetall
Original Assignee
Hoffmann La Roche
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA51988(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Ptc Therapeutics Inc filed Critical Hoffmann La Roche
Publication of MA51988A publication Critical patent/MA51988A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051988A 2014-05-15 2015-05-11 Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale MA51988A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15

Publications (1)

Publication Number Publication Date
MA51988A true MA51988A (fr) 2021-01-20

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051988A MA51988A (fr) 2014-05-15 2015-05-11 Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale
MA39995A MA39995B1 (fr) 2014-05-15 2015-05-11 Composés destinés à traiter l'amyotrophie spinale

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA39995A MA39995B1 (fr) 2014-05-15 2015-05-11 Composés destinés à traiter l'amyotrophie spinale

Country Status (36)

Country Link
US (1) US9969754B2 (fr)
EP (3) EP3143025B1 (fr)
JP (1) JP6236173B2 (fr)
KR (2) KR102256013B1 (fr)
CN (1) CN106459092B (fr)
AR (2) AR100442A1 (fr)
AU (1) AU2015261046C1 (fr)
BR (1) BR112016026205B1 (fr)
CA (1) CA2948561C (fr)
CL (1) CL2016002836A1 (fr)
CR (1) CR20160518A (fr)
DK (1) DK3143025T3 (fr)
EA (2) EA202090486A3 (fr)
ES (2) ES2761423T3 (fr)
FR (1) FR21C1039I2 (fr)
HR (2) HRP20192159T1 (fr)
HU (2) HUE046491T2 (fr)
IL (2) IL248653B (fr)
LT (1) LTC3143025I2 (fr)
MA (2) MA51988A (fr)
MX (1) MX371050B (fr)
MY (1) MY174284A (fr)
NL (1) NL301128I2 (fr)
NO (2) NO2021035I1 (fr)
NZ (1) NZ725008A (fr)
PE (1) PE20170128A1 (fr)
PH (1) PH12016502081B1 (fr)
PL (2) PL3143025T3 (fr)
PT (1) PT3143025T (fr)
RS (1) RS59718B1 (fr)
SG (1) SG11201609497TA (fr)
SI (2) SI3663296T1 (fr)
TW (1) TWI667239B (fr)
UA (1) UA119670C2 (fr)
WO (1) WO2015173181A1 (fr)
ZA (1) ZA201607026B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3406252B1 (fr) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Composés pour le traitement de l'amyotrophie spinale
CA2915764A1 (fr) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Procede de criblage
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (fr) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Composés pour le traitement d'une amyotrophie spinale
EP3310169B1 (fr) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Procédés de modulation de l'épissage de l'arn
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
AR106652A1 (es) * 2015-11-12 2018-02-07 Hoffmann La Roche Compuestos para tratar la esclerosis lateral amiotrófica
CA3119019C (fr) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Composes et methodes pour traiter la maladie de huntington
EP3386978B1 (fr) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Dérivés de pipéridine pontés
JP2019535789A (ja) * 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
EP4151627A1 (fr) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Composés permettant de traiter la maladie de huntington
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
HRP20251594T1 (hr) * 2017-09-22 2026-01-30 F. Hoffmann - La Roche Ag Postupak priprave derivata 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona
ES3072590T3 (en) * 2017-10-03 2026-07-02 Hoffmann La Roche New treatment of sma
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (fr) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Composés hétéroaryles pour le traitement de la maladie de huntington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020004594A1 (fr) 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス Agent prophylactique ou thérapeutique pour amyotrophie spinale
CN120554386A (zh) * 2018-10-19 2025-08-29 豪夫迈·罗氏有限公司 新型吡啶并[1,2-a]嘧啶-4-酮衍生物、其制剂及制备方法
CA3139821A1 (fr) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Composes pour le traitement de la maladie de huntington
WO2020249577A1 (fr) 2019-06-12 2020-12-17 F. Hoffmann-La Roche Ag Nouveau traitement de sma
US12492214B2 (en) 2019-07-31 2025-12-09 Assia Chemical Industries Ltd. Solid state forms of Risdiplam and process for preparation thereof
MX2022012677A (es) * 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
WO2022048675A1 (fr) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Forme cristalline du risdiplam, son procédé de préparation et son utilisation
WO2022162107A1 (fr) 2021-02-01 2022-08-04 Sandoz Ag Forme cristalline de risdiplam
EP4308577B1 (fr) * 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG Nouveaux dérivés de thiadiazolopyrimidone
EP4308572B1 (fr) * 2021-03-17 2025-04-23 F. Hoffmann-La Roche AG Nouveaux dérivés de thiénopyrimidinone
CR20230437A (es) 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
KR102973992B1 (ko) * 2021-03-18 2026-06-08 에프. 호프만-라 로슈 아게 리스디플람의 제조 방법
EP4426306A1 (fr) 2021-10-06 2024-09-11 F. Hoffmann-La Roche AG Nouvelle administration combinée
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (fr) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
US20260098048A1 (en) * 2022-09-26 2026-04-09 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
JP2025534681A (ja) 2022-10-14 2025-10-17 ジェネンテック, インコーポレイテッド 脊髄性筋萎縮症の治療方法
EP4669647A1 (fr) * 2023-01-21 2025-12-31 Harman Finochem Limited Procédé de préparation de risdiplatine, nouveaux intermédiaires et leur procédé de préparation
WO2024218207A1 (fr) 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Dérivés de thiéno[3,2-b]pyridine
AU2024286618A1 (en) 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
CN117050096A (zh) * 2023-07-17 2023-11-14 杭州诺澳生物医药科技有限公司 一种利司扑兰的制备方法
AU2024365291A1 (en) 2023-10-27 2026-02-19 F. Hoffmann-La Roche Ag New composition for treating spinal muscular atrophy
WO2026125303A1 (fr) 2024-12-11 2026-06-18 F. Hoffmann-La Roche Ag Système d'expression génique inductible

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0920429T3 (da) * 1996-08-06 2003-05-12 Pfizer Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
CA2700841A1 (fr) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Composes d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
US8633019B2 (en) * 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
WO2010019236A1 (fr) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc Méthodes de traitement de l’atrophie musculaire spinale
JP2011529722A (ja) * 2008-08-14 2011-12-15 カーディアック ペースメイカーズ, インコーポレイテッド 音響通信リンクの性能評価および適合
MX352861B (es) * 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
MX357834B (es) * 2012-01-26 2018-07-26 Ptc Therapeutics Inc Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
EP3406252B1 (fr) * 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Composés pour le traitement de l'amyotrophie spinale
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy

Also Published As

Publication number Publication date
MA39995B1 (fr) 2019-11-29
EA035068B1 (ru) 2020-04-23
SI3663296T1 (sl) 2023-08-31
TW201609738A (zh) 2016-03-16
FR21C1039I1 (fr) 2021-10-15
US20170197990A1 (en) 2017-07-13
IL270027B (en) 2020-08-31
EP3663296A1 (fr) 2020-06-10
KR102213740B1 (ko) 2021-02-09
BR112016026205A8 (pt) 2021-07-20
PT3143025T (pt) 2019-12-03
ES2761423T3 (es) 2020-05-19
JP6236173B2 (ja) 2017-11-22
CA2948561C (fr) 2019-10-22
DK3143025T3 (da) 2019-12-09
NO2021035I1 (no) 2021-09-10
UA119670C2 (uk) 2019-07-25
HRP20230637T1 (hr) 2023-09-29
MX2016014547A (es) 2017-02-23
KR20210014219A (ko) 2021-02-08
IL248653B (en) 2019-11-28
FR21C1039I2 (fr) 2022-09-02
SG11201609497TA (en) 2016-12-29
AU2015261046B2 (en) 2019-04-18
EA202090486A2 (ru) 2020-06-30
HRP20192159T1 (hr) 2020-02-21
EP3663296B1 (fr) 2023-05-17
JP2017515863A (ja) 2017-06-15
PL3663296T3 (pl) 2023-08-07
BR112016026205B1 (pt) 2021-12-07
CN106459092B (zh) 2019-10-15
IL248653A0 (en) 2017-01-31
CL2016002836A1 (es) 2017-04-21
EP4241772A3 (fr) 2023-11-15
EA202090486A3 (ru) 2020-08-31
PH12016502081A1 (en) 2017-01-09
PE20170128A1 (es) 2017-03-16
AU2015261046A1 (en) 2016-10-27
RS59718B1 (sr) 2020-01-31
TWI667239B (zh) 2019-08-01
KR102256013B1 (ko) 2021-05-26
EP4241772A2 (fr) 2023-09-13
NL301128I1 (fr) 2021-09-22
NO2025038I1 (no) 2025-08-14
CR20160518A (es) 2017-02-21
AU2015261046C1 (en) 2019-07-25
US9969754B2 (en) 2018-05-15
KR20170003687A (ko) 2017-01-09
WO2015173181A1 (fr) 2015-11-19
LTC3143025I2 (fr) 2023-11-10
NL301128I2 (nl) 2021-10-25
PH12016502081B1 (en) 2022-11-23
MY174284A (en) 2020-04-01
EP3143025B1 (fr) 2019-10-09
CA2948561A1 (fr) 2015-11-19
BR112016026205A2 (pt) 2017-08-15
PL3143025T3 (pl) 2020-03-31
HUS2100037I1 (hu) 2021-10-28
AR131260A2 (es) 2025-03-05
ES2949660T3 (es) 2023-10-02
MX371050B (es) 2020-01-14
ZA201607026B (en) 2022-05-25
CN106459092A (zh) 2017-02-22
AR100442A1 (es) 2016-10-05
LTPA2021010I1 (fr) 2021-10-11
SI3143025T1 (sl) 2020-01-31
NZ725008A (en) 2019-11-29
EA201692280A1 (ru) 2018-07-31
HUE046491T2 (hu) 2020-03-30
EP3143025A1 (fr) 2017-03-22

Similar Documents

Publication Publication Date Title
FR21C1039I2 (fr) Composés destinés à traiter l'amyotrophie spinale
EP3434645A4 (fr) Procédé de préparation en continu de nanoplaquettes d'oxyde de graphène
EP3013345A4 (fr) Composés pour le traitement d'une amyotrophie spinale
EP3353841A4 (fr) Procédé de préparation et d'application de composites de carbone-sélénium
EP2819519A4 (fr) Composés pour le traitement de l'amyotrophie spinale
EP2828247A4 (fr) Composés pour le traitement de l'amyotrophie spinale
EP3647310A4 (fr) Procédé de préparation de 2,5-furandiméthylcarboxylate à partir d'hydroxyméthylfurfural
EP3706725A4 (fr) Processus pour la préparation de tapinarof
MA43099A (fr) Procédé pour la préparation de chlorure de vinyle
EP3383436A4 (fr) Procédé amélioré de préparation de vert d'indocyanine
MA55917A (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
EP3695433A4 (fr) Procédé de préparation d'échantillon de section transversale
EP3766869A4 (fr) Procédé simple de préparation d'avibactam
EP3341359A4 (fr) Procédé de préparation d'aprémilast
MA42423A (fr) Procédé de préparation d'un revêtement
EP3500551A4 (fr) Procédé de préparation de biphényles substitués
EP3511313A4 (fr) Procédé de préparation de 1,3-cyclohexanediméthanol
EP3696168A4 (fr) Procédé de préparation de 2-chloro-5-trifluorométhylpyridine
MA51870A (fr) Procédé pour la préparation de composés coupleurs de médicaments
EP3505525A4 (fr) Procédé de préparation de rubusoside
EP3519382A4 (fr) Procédé amélioré de préparation de lacosamide
EP3727377A4 (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
EP3311804A4 (fr) Procédé d'élaboration de microcapsules de type colloïdosome
EP3666756A4 (fr) Procédé de préparation de lévétiracétam
EP3533856A4 (fr) Procédé de préparation d'hexadécahydropyrène